>>According to the
Sensipar label, frequent monitoring of calcium levels is recommended, as a
significant number of patients being treated with Sensipar were associated
with the development of low serum calcium levels. In our opinion, this is not
a significant issue to prevent usage of Sensipar.<<
At first, I completely agreed with this, as folks on hemodialysis tend to have this monitored anyhow. If they don't it's easy enough. However, hemodialysis patients go to a center a few times a week, while some patients are on their own with peritoneal dialysis. For the latter, it might be an issue, unless they get checked for something else as frequently as they need their serum calcium checked. I am not sure about this.
Here's a quick look at the supposed advantages of the competing mAB ABGX is developing (with thanks to Erik for the summation):
Message 19769635
However, this product is years away, at best, being in PI.
Does anyone here follow NPSP's early stage neuro portfolio? It seems to me that a couple things could go into the clinic soon, such as GlyT-1, and the mGluRs:
npsp.com
Of course, those, being partnered with big pharma may move rather stealthily. Still, we ought to hear about them entering the clinic, as it would generate a milestone payment, a material event. The migraine drugs bother me a bit. This is a crowded field, and both NPS-1776 and ALX-0646 got returned to NPS by partners. Anyone know if they're actually going to try further development of one or the other or both?
Cheers, Tuck |
